

Prediction of Diabetes Using Serum C-Peptide

Hye Seung Jung

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Type 2 diabetes is generally regarded as an irreversible disease, and considering its effects on complications, prevention of diabetes is very important. Fortunately, type 2 diabetes is a preventable disease [1], and therefore the prediction of diabetes in high risk persons is a key issue. Such a prediction would be based on several genetic and environmental factors as well as insulin secretory capacity [2,3], because if the insulin secretion is enough to compensate for other risk factors, diabetes would not develop [4].

In this issue of *Endocrinology and Metabolism*, Kim et al. [5] suggested that C-peptide would be more effective in the prediction of diabetes compared to insulin. Among 140 adults without diabetes at baseline, 20% became diabetic during a mean follow-up of 55 months, and among the baseline examinations, C-peptide increase by glucose loading—which the authors referred to as the “C-peptidogenic index”—was the most predictive and independent index for future diabetes. Most previous studies have used serum insulin for the estimation of insulin secretion in the prediction of diabetes [2-4]; however, according to this study by Kim et al. [5], C-peptide measurement would be superior, especially during oral glucose tolerance tests. In addition, there is a report that the C-peptide based index was more closely correlated than the insulin-based index with β -cell mass in humans [6].

These findings that C-peptide is more related with β -cell mass and function than insulin might be a result of C-peptide metabolism being less vulnerable than insulin and more reproducible with lower variations [7,8].

Although this study was performed as a retrospective design, it is worth paying attention to the results because of the increased prevalence of prediabetes worldwide. Further investigation in large cohort as a prospective design would be needed to establish more accurate tools for the prediction of diabetes.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Hye Seung Jung <http://orcid.org/0000-0002-0221-7049>

REFERENCES

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393-403.
2. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. *Diabetes Care* 2013;36:3607-12.
3. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? *Diabetes Care* 2007;30:1544-8.

Corresponding author: Hye Seung Jung

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea

Tel: +82-2-2072-0240, **Fax:** +82-2-764-2199, **E-mail:** junghs@snu.ac.kr

Copyright © 2016 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

4. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. *Diabetes* 2005;54:166-74.
5. Kim JD, Kang SJ, Lee MK, Park SE, Rhee EJ, Park CY, et al. C-peptide-based index is more related to incident type 2 diabetes in non-diabetic subjects than insulin-based index. *Endocrinol Metab* 2016;31:320-7.
6. Meier JJ, Menge BA, Breuer TG, Muller CA, Tannapfel A, Uhl W, et al. Functional assessment of pancreatic beta-cell area in humans. *Diabetes* 2009;58:1595-603.
7. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. *Diabetes* 1992;41:368-77.
8. Utzschneider KM, Prigeon RL, Tong J, Gerchman F, Carr DB, Zraika S, et al. Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. *Diabetologia* 2007;50:2516-25.